newsfilter
← Latest News
Business Wire·

Humanigen Reports First Quarter 2022 Financial Results

Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate upd